Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity.
作者信息
Henn Wolfram
机构信息
Institute of Human Genetics, Saarland University, University Clinic Bldg. 68, 66421 Homburg-Saar, Germany.
出版信息
Vaccine. 2020 Jul 22;38(34):5396-5397. doi: 10.1016/j.vaccine.2020.06.058. Epub 2020 Jun 23.
Abstract
摘要
相似文献
1
Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity.未来严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗初始短缺时的分配标准及全球免疫所需措施。
Vaccine. 2020 Jul 22;38(34):5396-5397. doi: 10.1016/j.vaccine.2020.06.058. Epub 2020 Jun 23.
2
SARS-CoV-2: A New Song Recalls an Old Melody.SARS-CoV-2：一首新歌唤起旧旋律。
Cell Host Microbe. 2020 May 13;27(5):692-694. doi: 10.1016/j.chom.2020.04.019.
3
SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.严重急性呼吸综合征冠状病毒2：既往冠状病毒、免疫反应及疫苗研发
Bol Med Hosp Infant Mex. 2020;77(5):252-261. doi: 10.24875/BMHIM.20000191.
4
Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.基于刺突蛋白的 SARS 亚单位疫苗候选物的保护性免疫：冠状病毒疫苗开发的经验教训。
J Immunol Res. 2020 Jul 18;2020:7201752. doi: 10.1155/2020/7201752. eCollection 2020.
5
[Strategies for vaccine development of COVID-19].[新型冠状病毒肺炎疫苗研发策略]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):593-604. doi: 10.13345/j.cjb.200094.
6
Coronavirus vaccine trials have delivered their first results - but their promise is still unclear.冠状病毒疫苗试验已得出首批结果——但其前景仍不明朗。
Nature. 2020 May;581(7809):363-364. doi: 10.1038/d41586-020-01092-3.
7
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防：回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
8
[Not Available].[无可用内容]
MMW Fortschr Med. 2020 May;162(10):60. doi: 10.1007/s15006-020-0525-5.
9
Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees.在没有充分安全保障的情况下，不要急于部署新冠疫苗和药物。
Nature. 2020 Mar;579(7799):321. doi: 10.1038/d41586-020-00751-9.
10
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.鉴定 2019 新型冠状病毒的受体结合域（RBD）：作为病毒附着抑制剂和疫苗开发 RBD 蛋白的意义。
Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19.
引用本文的文献
1
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals.一种灭活的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗可诱导产生交叉中和的持久性抗体，并在小动物中提供针对病毒攻击的保护作用。
iScience. 2023 Feb 17;26(2):105949. doi: 10.1016/j.isci.2023.105949. Epub 2023 Jan 10.
2
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.两剂灭活疫苗后，mRNA COVID-19 疫苗减少剂量和标准加强剂量在健康成年人中的反应原性和免疫原性比较。
Vaccine. 2022 Sep 16;40(39):5657-5663. doi: 10.1016/j.vaccine.2022.08.033. Epub 2022 Aug 22.
3
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population.健康人群中皮内注射 ChAdOx1 nCoV-19 加强针的免疫原性和安全性
NPJ Vaccines. 2022 May 13;7(1):52. doi: 10.1038/s41541-022-00475-z.
4
Comparison of health-oriented cross-regional allocation strategies for the COVID-19 vaccine: a mathematical modelling study.面向健康的 COVID-19 疫苗跨区域分配策略比较：一项数学建模研究。
Ann Med. 2022 Dec;54(1):941-952. doi: 10.1080/07853890.2022.2060522.
5
Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.健康人群中两剂新型冠状病毒灭活疫苗接种后皮内注射BNT162b2 mRNA疫苗加强针的免疫原性和安全性
Vaccines (Basel). 2021 Nov 23;9(12):1375. doi: 10.3390/vaccines9121375.
6
Willingness to receive future COVID-19 vaccines following the COVID-19 epidemic in Shanghai, China.上海新冠肺炎疫情后接种未来新冠疫苗的意愿。
BMC Public Health. 2021 Jun 9;21(1):1103. doi: 10.1186/s12889-021-11174-0.
本文引用的文献
1
Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.预防老年人感染性疾病的疫苗：免疫挑战与未来展望。
Front Immunol. 2020 Apr 23;11:717. doi: 10.3389/fimmu.2020.00717. eCollection 2020.
2
A classification of the aims of vaccination and its relevance to transgenerational justice.疫苗接种目标的分类及其与代际正义的相关性。
J Glob Health. 2020 Jun;10(1):010341. doi: 10.7189/jogh.10.010341.
3
What are the underlying transmission patterns of COVID-19 outbreak? An age-specific social contact characterization.新冠疫情的潜在传播模式是什么？特定年龄的社会接触特征分析。
EClinicalMedicine. 2020 Apr 18;22:100354. doi: 10.1016/j.eclinm.2020.100354. eCollection 2020 May.
4
Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.伊朗暴发期间 SARS-CoV-2 的免疫反应和发病机制：与 SARS 和 MERS 的比较。
Rev Med Virol. 2020 May;30(3):e2107. doi: 10.1002/rmv.2107. Epub 2020 Apr 8.
5
Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.新冠疫情：美国食品药品监督管理局批准使用康复期血浆治疗重症患者。
BMJ. 2020 Mar 26;368:m1256. doi: 10.1136/bmj.m1256.
6
SARS-CoV-2 and COVID-19: The most important research questions.严重急性呼吸综合征冠状病毒2与冠状病毒病2019：最重要的研究问题。
Cell Biosci. 2020 Mar 16;10:40. doi: 10.1186/s13578-020-00404-4. eCollection 2020.
7
Covid-19: Trump sought to buy vaccine developer exclusively for US, say German officials.新冠疫情：德国官员称，特朗普曾试图独家收购疫苗研发商供美国使用。
BMJ. 2020 Mar 17;368:m1100. doi: 10.1136/bmj.m1100.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.基于 SARS-CoV 免疫学研究的 COVID-19 冠状病毒（SARS-CoV-2）潜在疫苗靶点的初步鉴定。
Viruses. 2020 Feb 25;12(3):254. doi: 10.3390/v12030254.
10
Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage.疫苗更新：新型疫苗的最新进展，以及安全监测和疫苗短缺的新方法。
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S123-S139. doi: 10.1002/jcph.1140.
Zotero 插件